Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Xeltis Hemodialysis Access Graft (aXess) US Study

NCT: NCT06494631 · ENROLLING_BY_INVITATION

NCT IDNCT06494631
StatusENROLLING_BY_INVITATION
Start Date2024-11-11
Completion2032-01
SponsorXeltis (INDUSTRY)
First posted
Last updated

Brief Summary

A multi-center, prospective, single-arm, non-randomized, staged, pivotal clinical study to evaluate the safety and performance of the aXess graft in subjects aged 18 and above, diagnosed with end-stage kidney disease, and possessing an estimated glomerular filtration rate (eGFR) less than 20 ml/min, who intend to undergo hemodialysis but are considered unsuitable candidates for fistula creation by the investigating surgeon.

Frequently Asked Questions

What is Xeltis Hemodialysis Access Graft (aXess) US Study?

Xeltis Hemodialysis Access Graft (aXess) US Study is a clinical trial registered under NCT06494631. Current status: ENROLLING_BY_INVITATION.

What is the status of NCT06494631?

The current status of NCT06494631 (Xeltis Hemodialysis Access Graft (aXess) US Study) is: ENROLLING_BY_INVITATION.

When did Xeltis Hemodialysis Access Graft (aXess) US Study start?

Xeltis Hemodialysis Access Graft (aXess) US Study started on 2024-11-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.